TABLE 1.
ELISA titers, concentrations, and AIs of MAbs against purified DENV-2 particles and the NS1 glycoprotein
| MAb | Concn (mg/ml) | Specificity (serotypes) | ELISA titer (concn [ng/ml])a
|
AI (%)b | |
|---|---|---|---|---|---|
| Without DEA | With DEA | ||||
| MAbs against DENV-2 NS1 glycoprotein | |||||
| 1H7.4 | 4.14 | NS1 (DENV-2) | 6.12 (3.14) | 5.68 (8.65) | 36.30 |
| 5H4.3 | 2.78 | NS1 (DENV-2 and -4) | 5.21 (17.14) | 4.75 (49.44) | 34.67 |
| 3D1.4 | 3.35 | NS1(DENV-1 to -4) | 5.88 (4.42) | 5.02 (31.99) | 13.82 |
| 1G5.3 | 2.57 | NS1 (DENV-2 and -4) | 5.65 (5.75) | 4.82 (38.90) | 14.78 |
| 1G5.4-A1-C3 | 2.36 | NS1 (DENV-1 to -4) | 5.17 (15.95) | 3.92 (283.73) | 5.62 |
| 1C6.3 | 1.47 | NS1 (DENV-1 to -4) | 4.52 (44.39) | 3.17 (993.84) | 4.47 |
| 2C5.1 | 3.28 | E (DENV-1 to -4) | 2.28 (17,213.69) | 0.74 (596,861.88) | 2.88 |
| MAbs against DENV-2 particles | |||||
| 1H7.4 | 4.14 | NS1 (DENV-2) | 0.62 (993,116.83) | ||
| 5H4.3 | 2.78 | NS1 (DENV-2 and -4) | 0.80 (440,600.31) | ||
| 3D1.4 | 3.35 | NS1 (DENV-1 to -4) | 2.02 (31,992.25) | 0.82 (507,043.02) | 6.31 |
| 1G5.3 | 2.57 | NS1 (DENV-2 and -4) | 3.43 (954.85) | 1.80 (40,731.76) | 2.34 |
| 1G5.4-A1-C3 | 2.36 | NS1 (DENV-1 to -4) | 3.37 (1,006.73) | 1.77 (40,078.55) | 2.51 |
| 1C6.3 | 1.47 | NS1 (DENV-1 to -4) | 2.51 (4,543.73) | 0.83 (217,428.93) | 2.09 |
| 2C5.1 | 3.28 | E (DENV-1 to -4) | 5.46 (11.37) | 4.51 (101.36) | 11.21 |
a
Average 1/log10t50 of MAbs in the presence or absence of DEA from triplicate assays, with the MAb concentration given in parentheses.
b
AI (%) = reciprocal anti-log10t50 with DEA/reciprocal anti-log10t50 without DEA × 100 = MAb concentration (ng/ml) at 1/log10t50 without DEA/MAb concentration (ng/ml) at 1/log10t50 with DEA × 100.